SPOP突变在前列腺癌中的预后与预测作用:系统综述与Meta分析
该系统综述与Meta分析检索截至2024年1月29日的PubMed、Embase和Scopus,纳入26项研究,比较SPOP突变型与野生型前列腺癌患者的生存结局。结果显示SPOP突变型在局限性及转移性前列腺癌中均与更优预后相关,且在接受雄激素剥夺治疗±雄激素受体信号抑制剂时预后更好。
要点
- SPOP突变型前列腺癌患者的肿瘤学结局似乎优于SPOP野生型患者。
- 转移性去势抵抗性前列腺癌中仅阿比特龙显示SPOP突变患者PFS和OS改善,但数据有限。
- 多西他赛治疗中SPOP突变与PFS(p=0.80)或OS(p=0.27)改善无关。
核心结论
- SPOP突变型前列腺癌患者似乎表现出优于SPOP野生型患者的肿瘤学结局。
- 作者建议在此类患者中探索量身定制的风险分层和治疗策略。
- 作者认为,对于SPOP突变型前列腺癌患者,应在临床试验中探索省略化疗的较低强度治疗。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase和Scopus截至2024年1月29日的文献。
- 从669条记录中纳入26项研究(包括5篇摘要)进行分析。
- Meta分析纳入比较SPOP突变型与SPOP野生型前列腺癌生存结局的研究。
主要发现
- 局限性前列腺癌中,SPOP突变型较野生型的无转移生存期改善(HR 0.72,95%CI 0.59-0.88;p<0.01)。
- 转移性前列腺癌中,SPOP突变型较野生型的总生存期改善(HR 0.64,95%CI 0.53-0.76;p<0.01)。
- 转移性前列腺癌接受雄激素剥夺治疗±雄激素受体信号抑制剂时,SPOP突变与无进展生存期改善相关(HR 0.51,95%CI 0.35-0.76,p<0.01)。
- 转移性前列腺癌接受雄激素剥夺治疗±雄激素受体信号抑制剂时,SPOP突变与总生存期改善相关(HR 0.60,95%CI 0.46-0.79,p<0.01)。
- 转移性去势抵抗性前列腺癌中,仅阿比特龙显示SPOP突变型较野生型的无进展生存期和总生存期改善,但数据有限。
关键数值与推荐
- SPOP突变型较野生型在局限性前列腺癌中的无转移生存期HR 0.72(95%CI 0.59-0.88;p<0.01)。
- SPOP突变型较野生型在转移性前列腺癌中的总生存期HR 0.64(95%CI 0.53-0.76;p<0.01)。
- 转移性前列腺癌接受雄激素剥夺治疗±雄激素受体信号抑制剂时,SPOP突变型较野生型的无进展生存期HR 0.51(95%CI 0.35-0.76,p<0.01)。
- 转移性前列腺癌接受雄激素剥夺治疗±雄激素受体信号抑制剂时,SPOP突变型较野生型的总生存期HR 0.60(95%CI 0.46-0.79,p<0.01)。
- 多西他赛治疗中,SPOP突变与无进展生存期改善无关(p=0.80),与总生存期改善无关(p=0.27)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为,对于SPOP突变型前列腺癌患者,应在临床试验中探索省略化疗的较低强度治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Mutations in the speckle-type POZ (SPOP) gene are frequently identified in prostate cancer (PC); yet, prognostic implications for affected patients remain unclear. Limited consensus exists regarding tailored treatments for SPOP-mutant (SPOPmut) PC. OBJECTIVE: To elucidate the prognostic and predictive significance of SPOP mutations across distinct PC stages and treatments. EVIDENCE ACQUISITION: A systematic literature search of PubMed, Embase, and Scopus was conducted up to January 29, 2024. The meta-analysis included studies comparing survival outcomes between SPOPmut and SPOP wild-type (SPOPwt) PC. EVIDENCE SYNTHESIS: From 669 records, 26 studies (including five abstracts) were analyzed. A meta-analysis of metastasis-free survival in localized (hazard ratio [HR]: 0.72, 95% confidence interval [CI]: 0.59-0.88; p < 0.01) and overall survival (OS) in metastatic PC (HR: 0.64, 95% CI: 0.53-0.76; p < 0.01) showed a favorable prognosis for patients with SPOPmut PC. In metastatic settings, SPOP mutations correlated with improved progression-free survival (PFS) and OS in patients undergoing androgen deprivation therapy ± androgen receptor signaling inhibitor (HR: 0.51, 95% CI: 0.35-0.76, p < 0.01, and HR: 0.60, 95% CI:0.46-0.79, p < 0.01, respectively). In metastatic castration-resistant PC, only abiraterone provided improved PFS and OS to patients with SPOP mutations compared with patients with SPOPwt, but data were limited. SPOP mutations did not correlate with improved PFS (p = 0.80) or OS (p = 0.27) for docetaxel. CONCLUSIONS: Patients with SPOPmut PC seem to exhibit superior oncological outcomes compared with patients with SPOPwt. Tailored risk stratification and treatment approaches should be explored in such patients. PATIENT SUMMARY: Speckle-type POZ (SPOP) mutations could be a favorable prognostic factor in patients with prostate cancer (PC) and may also predict better progression-free and overall survival than treatment with hormonal agents. Therefore, less intensified treatments omitting chemotherapy for patients with SPOP-mutant PC should be explored in clinical trials.
引用
- Pedrani M, Salfi G, Merler S, et al. Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2024. PMID: 38704358. doi:10.1016/j.euo.2024.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。